Shares of Danaher DHR fell 1% in pre-market trading after the company reported Q3 results.
Quarterly Results
Earnings per share increased 48.28% over the past year to $1.72, which beat the estimate of $1.36.
Revenue of $5,883,000,000 rose by 16.80% year over year, which beat the estimate of $5,510,000,000.
Looking Ahead
Earnings guidance hasn't been issued by the company for now.
Revenue guidance hasn't been issued by the company for now.
Details Of The Call
Date: Oct 22, 2020
Time: 08:00 AM
ET Webcast URL: https://www.webcaster4.com/Webcast/Page/758/37429
Recent Stock Performance
52-week high: $229.75
Company's 52-week low was at $119.60
Price action over last quarter: Up 16.02%
Company Profile
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which adds to its life sciences segment.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
